Replies to post #261433 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

This Qtr, 1QFY2018, which ends CY Jun30, 2017 in 2 weeks.

All indications pointing to $ELTP's own ANDA for OxyContin.

Elite successfully completed a BE study for generic oxycodone this year as well. Oxycodone is the largest abuse deterrent product currently on the market. It has an IMS data of over $2.5 billion. As soon as we complete the required in vitro and [indiscernible] studies we will be filing a generic for oxycodone. I expect that that will happen this quarter.

We have this successful deal for Oxycodone generic that uses the physical approach for abuse deterrent technology. We expect to file this product this quarter, oxycodone has a market IMS data of $2.5 billion.

[Don'tDrinkTheKoolAid]

It's nice to dream isn't it.?